Hemostemix (CVE:HEM) Hits New 1-Year Low – Here’s Why

Hemostemix Inc. (CVE:HEM)’s share price reached a new 52-week low during mid-day trading on Monday . The stock traded as low as C$0.06 and last traded at C$0.07, with a volume of 70000 shares. The stock had previously closed at C$0.07.

Hemostemix Trading Up 7.7%

The business’s fifty day moving average price is C$0.08 and its 200 day moving average price is C$0.09. The company has a quick ratio of 0.48, a current ratio of 1.54 and a debt-to-equity ratio of -99.52. The firm has a market capitalization of C$13.19 million, a PE ratio of -2.59 and a beta of 0.25.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.